News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
This opens up a huge market for the company’s Magnezis implants in India
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
According to industry sales data, the 10mg strength of Afinitor generated annual sales of US $ 392 million during the twelve months ending July 2021
Subscribe To Our Newsletter & Stay Updated
